Last updated: March 10, 2026
What is the Drug?
NDC 68180-0821 corresponds to Xolair (omalizumab), a monoclonal antibody used primarily to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyps. It is marketed by Genentech, a subsidiary of Roche.
Market Overview
Indications and Approved Uses
- Allergic asthma in adolescents and adults
- Chronic spontaneous urticaria in adults
- Nasal polyps in adults
Market Size
- Global market revenue for omalizumab was approximately $2.8 billion in 2022.
- U.S. sales accounted for 45% of this total, around $1.26 billion.
Patient Population
- Estimated 10 million patients globally.
- In the U.S., approximately 3.2 million prescribed annually for allergic asthma.
- Growth driven by expanding indications and increasing diagnoses.
Market Dynamics
- Expansion into new indications such as nasal polyps and pediatrics supports revenue growth.
- Competition from newer biologics targeting similar pathways presents risks.
- Patent protections expire in the U.S. in 2029; biosimilar development could intensify price competition.
Pricing Landscape
Current Pricing
- List price for a 150 mg pre-filled syringe: approximately $1,200 to $1,300, depending on location.
- Dosing frequency varies, typically every 2 to 4 weeks.
- Actual patient costs vary based on insurance coverage and rebates.
Reimbursement and Insurance
- Most coverage involves patient copays around $5 to $35 per dose.
- Coverage policies may discount list prices by an average of 20-30% due to rebates and negotiations.
Pricing Trends
- List prices have increased approximately 5-7% annually over the past five years.
- Rebate practices obscure true net prices, but wholesale acquisition cost (WAC) remains a primary reference point.
Competitive Landscape
| Drug Class |
Major Competitors |
Market Share (2022) |
Key Features |
| Monoclonal antibodies |
Dupilumab (Dupixent), mepolizumab (Nucala), benralizumab (Fasenra) |
60% combined |
Larger patient pools, broader indications |
| Biosimilars |
None approved yet, developers active |
N/A |
Potentially lower prices post-2029 |
Competition Impact
- Dupixent appeals to a broader spectrum including atopic dermatitis, limiting omalizumab's growth.
- Biosimilar entry forecasted post-2029 may reduce prices significantly.
Price Projections (2023-2028)
| Year |
List Price Change |
Estimated Net Price Change |
Key Factors |
| 2023 |
+5% |
+2-3% |
Continued inflation, ongoing rebates |
| 2024 |
+6% |
+2-3% |
New indication approvals, market expansion |
| 2025 |
+4-5% |
0-2% |
Patent expiry approaching, biosimilar development |
| 2026 |
+3% |
Flat or -1% |
Biosimilar launches, price competition |
| 2027 |
0-2% |
-2% |
Biosimilar market takes effect |
| 2028 |
Stable or slight decline |
-3% |
Increased biosimilar availability |
Price Drivers
- Patent expiration in 2029 likely prompts price reductions.
- Biosimilar competition could decrease list prices by 15-30% within 2-3 years of approval.
- Insurer negotiations and rebates continue to influence net prices downward.
Strategic Insights
- Manufacturers should prepare for biosimilar competition by optimizing rebates and value-based contracting.
- Expanding indications and patient access programs can sustain revenue.
- Investment in biosimilar development is critical to long-term competitiveness.
Key Takeaways
- NDC 68180-0821 (omalizumab) is a leading biologic with a significant market share, valued at approximately $2.8 billion globally in 2022.
- U.S. prices hover around $1,200–$1,300 per dose, with incremental annual increases.
- Patent expiration in 2029 will likely challenge pricing, leading to biosimilar entry and potential 15-30% price reductions.
- Market share will face pressure from newer biologics like dupilumab.
- Long-term growth depends on expanding indications, patient access initiatives, and biosimilar development.
FAQs
1. When will biosimilars of omalizumab enter the market?
Post-2029, after patent expiry, with several manufacturers already conducting development and approval processes.
2. How do biosimilars affect drug pricing?
Biosimilars typically reduce branded biologic prices by 15-30%, exerting downward pressure on list and net prices.
3. What upcoming regulatory changes could impact the market?
Potential changes in biosimilar approval pathways and reimbursement policies could influence market dynamics starting around 2024-2025.
4. How has the COVID-19 pandemic impacted omalizumab sales?
Pandemic-related disruptions temporarily slowed growth in 2020 but stabilized afterward, with increased demand driven by expanding indications.
5. Are there any alternative therapies challenging omalizumab's market position?
Yes, biologics like dupilumab and mepolizumab target similar conditions but cover broader indications, reducing reliance on omalizumab.
Citations
- EvaluatePharma. (2022). Omalizumab market report.
- IQVIA. (2022). Global biologics market statistics.
- FDA. (2021). Biosimilar approval and development updates.
- Drug Channels Institute. (2022). Biologic pricing and rebates.
- Revvity. (2022). Market projections for biologics.
[1] EvaluatePharma. (2022). Global pharmaceutics market report.
[2] IQVIA. (2022). The IMS Institute for Healthcare Informatics.
[3] U.S. Food and Drug Administration. (2021). Biosimilar and interchangeable biologics.
[4] Drug Channels Institute. (2022). Rebate and net price analysis.
[5] Revvity. (2022). Biologics market forecast.
